Cemex S.A.B. de C.V. Sponsored ADR vs Inovio Pharmaceuticals Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.56 (market cap $13.79B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is far larger — about 122.9× Inovio Pharmaceuticals Inc's market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 1 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| CX | INO | |
|---|---|---|
Market Cap | $13.79B | $112.19M |
Volume | 3,993,982 | 3,201,278 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $2.60 |
52-Week Low | $9.15 | $0.66 |
Typical Hold Time | 1 Days | 43 Days |
Enterprise Value | $19.79B | $83.51M |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →